Jian Xie, President and Chief Operating Officer of Fulgent Genetics, Inc. (NASDAQ:FLGT), recently completed the sale of company stock. On May 27, 2026, Mr. Xie divested 1,201 shares of the firm's common stock, realizing a total value of $21,137.
The transaction involved selling the shares at prices ranging from $17.39 to $17.76 per share, resulting in a weighted-average sale price of $17.60 per share. This stock activity occurred while FLGT's current trading price stood at $18.24, reflecting a significant return over the last month despite facing year-to-date operational challenges.
According to company statements, this divestment was executed specifically to satisfy tax withholding obligations that arose following the vesting of certain restricted stock units previously granted to Mr. Xie on February 26, 2024.
Share Holdings and Financial Stability
Following the recent sale, Mr. Xie maintains direct ownership of 369,751 shares of Fulgent Genetics common stock. Furthermore, his indirect holdings total 220,816 shares via The Hsieh Family Dynasty Trust, an entity established on January 27, 2010, where Mr. Xie serves as a member of the investment committee. It is noted that he disclaims beneficial interest in these specific shares except for any direct pecuniary interest.
From a corporate health perspective, Fulgent Genetics reports maintaining a solid balance sheet. The company's current ratio stands at 5.31, indicating that it possesses more cash reserves than total debt obligations are due.
Q1 Performance and Strategic Developments
The company recently released its financial results for the first quarter of 2026. These reported figures showed an earnings per share (EPS) loss of -$0.36, which was substantially below the consensus analyst expectation of -$0.11. Revenue also missed forecasts, reaching $71.1 million when analysts had anticipated $72.68 million.
The shortfall in revenue was explicitly linked to a major customer opting to bring its testing capabilities in-house, an action that significantly impacted Fulgent's top line performance. Despite these financial headwinds, the company is advancing several key strategic initiatives designed to expand its services and address market challenges.
Partnerships and Clinical Progress
In a notable development, Fulgent Genetics is collaborating with Foundation Medicine. This partnership aims to launch a new pharmacogenetic testing service called FoundationOne PGx. The goal of this service is to improve cancer care by identifying genetic variations related to medication metabolism. Once launched, the service will be accessible within the United States through Foundation Medicine’s established portal.
On the clinical front, Fulgent also released interim data pertaining to its Phase 2 trial for a novel oncology drug, FID-007. This drug is being tested in combination with cetuximab and focuses on patients diagnosed with recurrent or metastatic head and neck squamous cell carcinoma. These ongoing activities underscore Fulgent Genetics' commitment to developing new offerings even as it navigates recent financial performance challenges.